ホーム › バーキットリンパ腫 › ニューヨーク › New York City
New York City、NYにおけるバーキットリンパ腫の臨床試験
New York Cityとその周辺地域（約30マイル以内）の拠点で、バーキットリンパ腫に関する13件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
被験者募集中第3相
- Memorial Sloan Kettering Cancer Center, New York
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
被験者募集中第2相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- 他1件
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
被験者募集中第3相
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
被験者募集中第2相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
被験者募集中第3相
- David H. Koch Center for Cancer Care, New York
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
被験者募集中第1相
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
被験者募集中第2相
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
被験者募集中第3相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- 他2件
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
被験者募集中第1/2相
- Research Site, New York
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center, New York
Study of SGR-1505 in Mature B-Cell Neoplasms
被験者募集中第1相
- Weill Cornell, New York
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
他の都市におけるバーキットリンパ腫の試験
- Houston, TX21件の研究
- Philadelphia, PA16件の研究
- Milwaukee, WI16件の研究
- Chicago, IL15件の研究
- Cincinnati, OH13件の研究
- Atlanta, GA12件の研究
- Aurora, CO11件の研究
- Seattle, WA11件の研究
- Durham, NC10件の研究
- Kansas City, MO10件の研究
- Boston, MA10件の研究
- Los Angeles, CA10件の研究
New York Cityにおける他の研究
- 乳がん136件の研究
- 非小細胞肺癌121件の研究
- がん（全種類）109件の研究
- 前立腺がん103件の研究
- 転移性癌93件の研究
- 大腸癌78件の研究
- 卵巣がん69件の研究
- 肺がん60件の研究
- 多発性骨髄腫60件の研究
- 膵臓がん60件の研究
- 子宮内膜がん52件の研究
- 急性骨髄性白血病51件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。